JP2013516393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516393A5 JP2013516393A5 JP2012546344A JP2012546344A JP2013516393A5 JP 2013516393 A5 JP2013516393 A5 JP 2013516393A5 JP 2012546344 A JP2012546344 A JP 2012546344A JP 2012546344 A JP2012546344 A JP 2012546344A JP 2013516393 A5 JP2013516393 A5 JP 2013516393A5
- Authority
- JP
- Japan
- Prior art keywords
- halo
- lower alkyl
- optionally substituted
- pharmaceutically acceptable
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000011780 sodium chloride Substances 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 54
- 125000005843 halogen group Chemical group 0.000 description 42
- 125000003545 alkoxy group Chemical group 0.000 description 36
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 32
- 125000000623 heterocyclic group Chemical group 0.000 description 18
- -1 cyan Chemical group 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 239000001257 hydrogen Substances 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000005418 aryl aryl group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 2
- 125000005842 heteroatoms Chemical group 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- PTRJHYDRYXRGEL-UHFFFAOYSA-N 2,3,5,6-tetrahydropyran Chemical group [CH]1CCOCC1 PTRJHYDRYXRGEL-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XUIRHRWOJCYEDJ-UHFFFAOYSA-N 7-fluoroquinoline Chemical compound C1=CC=NC2=CC(F)=CC=C21 XUIRHRWOJCYEDJ-UHFFFAOYSA-N 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009076321 | 2009-12-31 | ||
| CNPCT/CN2009/076321 | 2009-12-31 | ||
| PCT/CN2010/080499 WO2011079804A1 (en) | 2009-12-31 | 2010-12-30 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013122502A Division JP2013209418A (ja) | 2009-12-31 | 2013-06-11 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013516393A JP2013516393A (ja) | 2013-05-13 |
| JP2013516393A5 true JP2013516393A5 (US20040106767A1-20040603-C00005.png) | 2013-08-01 |
| JP5337313B2 JP5337313B2 (ja) | 2013-11-06 |
Family
ID=44226181
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012546344A Active JP5337313B2 (ja) | 2009-12-31 | 2010-12-30 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
| JP2013122502A Pending JP2013209418A (ja) | 2009-12-31 | 2013-06-11 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
| JP2016074893A Active JP6194046B2 (ja) | 2009-12-31 | 2016-04-04 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
| JP2017155493A Active JP6486999B2 (ja) | 2009-12-31 | 2017-08-10 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
| JP2019028197A Active JP6647434B2 (ja) | 2009-12-31 | 2019-02-20 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013122502A Pending JP2013209418A (ja) | 2009-12-31 | 2013-06-11 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
| JP2016074893A Active JP6194046B2 (ja) | 2009-12-31 | 2016-04-04 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
| JP2017155493A Active JP6486999B2 (ja) | 2009-12-31 | 2017-08-10 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
| JP2019028197A Active JP6647434B2 (ja) | 2009-12-31 | 2019-02-20 | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
Country Status (38)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61281B1 (sr) * | 2009-12-31 | 2021-02-26 | Hutchison Medipharma Ltd | Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora |
| CN103068824B (zh) * | 2010-05-17 | 2017-09-08 | 印蔻真治疗公司 | 作为蛋白激酶调节剂的新型3,5‑二取代‑3h‑咪唑并[4,5‑b]吡啶和3,5‑二取代‑3h‑[1,2,3]三唑并[4,5‑b]吡啶化合物 |
| CN103030654A (zh) * | 2011-10-09 | 2013-04-10 | 济南赛文医药技术有限公司 | 一种小分子c-Met蛋白激酶抑制剂 |
| CN102516046A (zh) * | 2011-11-22 | 2012-06-27 | 太仓市运通化工厂 | 一种2-溴丙醛的合成方法 |
| BR112014024251A8 (pt) * | 2012-03-30 | 2018-01-23 | Rhizen Pharmaceuticals S A | novos compostos piridina 3,5-dissubstituída-3h-imidazo [4,5-b] e piridina 3,5-dissubstituída -3h-[1,2,3]triazolo[4,5-b] como moduladores de quinases de proteína c-met |
| CA2776178A1 (en) | 2012-04-05 | 2013-10-05 | Hydro-Quebec | Ionic compounds |
| KR101745741B1 (ko) | 2012-08-13 | 2017-06-12 | 한국화학연구원 | 신규한 트리아졸로 피라진 유도체 및 그의 용도 |
| RU2655604C2 (ru) | 2013-01-11 | 2018-05-29 | Фуджифилм Корпорэйшн | Азотсодержащее гетероциклическое соединение или его соль |
| JP5894714B1 (ja) | 2013-03-06 | 2016-03-30 | アストラゼネカ アクチボラグ | 上皮成長因子受容体の活性化変異型のキナゾリン阻害剤 |
| CN103265468A (zh) * | 2013-06-17 | 2013-08-28 | 连云港盛和生物科技有限公司 | 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法 |
| EP2818471A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 |
| CN104703988B (zh) * | 2013-09-30 | 2017-04-12 | 韩国化学研究院 | 新的三唑并吡嗪衍生物及其用途 |
| EA201890061A3 (ru) * | 2013-12-26 | 2018-09-28 | Игнита, Инк. | Производные пиразоло[1,5-a]пиридина и способы их применения |
| JP2016048495A (ja) * | 2014-08-28 | 2016-04-07 | 京セラ株式会社 | 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法 |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| CN106928233B (zh) * | 2015-12-31 | 2021-02-12 | 上海医药集团股份有限公司 | 喹啉类化合物的盐，其晶型、制备方法、组合物与应用 |
| GB201616116D0 (en) | 2016-09-22 | 2016-11-09 | Astrazeneca Ab | Use of c-Met inhibitors to treat cancers harbouring MET mutations |
| KR20180092096A (ko) * | 2017-02-08 | 2018-08-17 | 에이비온 주식회사 | 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법 |
| EP3985002A1 (en) | 2017-03-01 | 2022-04-20 | Achillion Pharmaceuticals, Inc. | Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| ES2933513T3 (es) | 2017-03-01 | 2023-02-09 | Achillion Pharmaceuticals Inc | Compuestos macrocíclicos para el tratamiento de trastornos médicos |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| CN108570053A (zh) * | 2017-03-13 | 2018-09-25 | 中国科学院上海药物研究所 | 五元并六元杂环化合物、制备方法、中间体、组合和应用 |
| KR101924801B1 (ko) | 2017-08-16 | 2018-12-04 | 한국원자력의학원 | 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물 |
| HU231333B1 (hu) | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
| EP3846803A4 (en) | 2018-09-06 | 2022-08-10 | Achillion Pharmaceuticals, Inc. | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
| EP3847174A4 (en) | 2018-09-06 | 2022-06-15 | Achillion Pharmaceuticals, Inc. | MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS |
| MX2021002794A (es) * | 2018-09-11 | 2021-08-11 | Astrazeneca Ab | Metodo mejorado para la fabricacion de 3-[(1s)-1-imidazo[1,2-a]pir idin-6- iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina y formas polimorficas de la misma. |
| MX2021003425A (es) | 2018-09-25 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| CA3118218A1 (en) * | 2018-10-30 | 2020-05-07 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors |
| SG11202105872RA (en) | 2018-12-14 | 2021-07-29 | Beta Pharma Inc | Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof |
| AU2020317381A1 (en) * | 2019-07-22 | 2022-02-10 | Repare Therapeutics Inc. | Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors |
| CN115362162A (zh) * | 2020-02-20 | 2022-11-18 | 艾其林医药公司 | 用于治疗补体因子d介导的障碍的杂芳基化合物 |
| WO2021229605A1 (en) * | 2020-05-14 | 2021-11-18 | Dr. Reddy's Laboratories Limited | Process for preparation of savolitinib and its intermediates |
| US20240026401A1 (en) * | 2020-09-28 | 2024-01-25 | Codexis, Inc. | Engineered biocatalysts and methods for synthesizing chiral amines |
| US20240076285A1 (en) * | 2020-12-16 | 2024-03-07 | Shankar Venkatraman | Compounds and compositions for treating conditions associated with sting activity |
| KR102659095B1 (ko) | 2021-01-08 | 2024-04-19 | 에이비온 주식회사 | 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법 |
| CN113278019A (zh) * | 2021-05-31 | 2021-08-20 | 河南偶联生物科技有限公司 | 一种咪唑并[1,2-a]吡啶类化合物的合成方法 |
| WO2023205722A1 (en) * | 2022-04-20 | 2023-10-26 | Engrail Therapeutics, Inc. | Gabaa receptor modulator salts, particles, and uses thereof |
| WO2024008929A1 (en) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
| WO2024026410A2 (en) * | 2022-07-29 | 2024-02-01 | Baylor College Of Medicine | Neurotrophic receptor tyrosine kinase (ntrk) inhibitors and methods using same |
| CN115611802B (zh) * | 2022-12-02 | 2023-03-14 | 北京迪泰医药科技有限公司 | 一种3-乙酰基-2-氯吡啶的合成方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| US5977134A (en) * | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US7674791B2 (en) | 2003-04-09 | 2010-03-09 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
| US6979505B2 (en) * | 2003-06-09 | 2005-12-27 | Utc Fuel Cells, Llc | Method and apparatus for removal of contaminants from a hydrogen processor feed stream, as in a fuel cell power plant |
| US7122548B2 (en) | 2003-07-02 | 2006-10-17 | Sugen, Inc. | Triazolotriazine compounds and uses thereof |
| CA2530589A1 (en) * | 2003-07-02 | 2005-01-20 | Sugen Inc. | Arylmethyl triazolo and imidazopyrazines as c-met inhibitors |
| US20050070542A1 (en) | 2003-09-03 | 2005-03-31 | Hodgetts Kevin J. | 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
| BRPI0513916A (pt) | 2004-07-27 | 2008-05-20 | Sgx Pharmaceuticals Inc | moduladores de pirrol-piridina cinase |
| EP1786811A2 (en) | 2004-08-18 | 2007-05-23 | Pharmacia & Upjohn Company LLC | Triazolopyridine compounds |
| CN101119996A (zh) * | 2005-02-16 | 2008-02-06 | 阿斯利康(瑞典)有限公司 | 化学化合物 |
| CA2598076A1 (en) * | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Chemical compounds |
| AU2006320580B2 (en) | 2005-11-30 | 2011-06-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Met and uses thereof |
| BRPI0620292B1 (pt) | 2005-12-21 | 2021-08-24 | Janssen Pharmaceutica N. V. | Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto |
| NL2000613C2 (nl) * | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| EP2032578A2 (en) | 2006-05-30 | 2009-03-11 | Pfizer Products Incorporated | Triazolopyridazine derivatives |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (es) * | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| WO2008021781A1 (en) | 2006-08-07 | 2008-02-21 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| CA2663528A1 (en) | 2006-09-18 | 2008-03-27 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of c-met and uses thereof |
| KR101083177B1 (ko) * | 2006-10-23 | 2011-11-11 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 트리아졸로-피리다진 단백질 키나제 조정제 |
| PL2084162T3 (pl) | 2006-10-23 | 2013-01-31 | Sgx Pharmaceuticals Inc | Bicykliczne triazole jako modulatory kinaz białkowych |
| AU2007323725B2 (en) | 2006-11-22 | 2014-02-20 | Incyte Holdings Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| EP2078020A4 (en) | 2007-04-10 | 2011-10-19 | Sgx Pharmaceuticals Inc | HETEROCYCLIC MODULATORS WITH FUSED CYCLES FOR KINASES |
| US8148369B2 (en) | 2007-05-10 | 2012-04-03 | Janssen Pharmaceutica Nv | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| CA2717034A1 (en) | 2008-02-28 | 2009-09-03 | Pascal Furet | Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease |
| CA2724715A1 (en) | 2008-05-22 | 2009-11-26 | Amgen Inc. | Heterocycles as protein kinase inhibitors |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| DE102008037790A1 (de) | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclische Triazolderivate |
| CA2770873A1 (en) * | 2009-08-12 | 2011-02-17 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
| EP2467383A1 (en) * | 2009-08-20 | 2012-06-27 | Novartis AG | Heterocyclic oxime compounds |
| RS61281B1 (sr) * | 2009-12-31 | 2021-02-26 | Hutchison Medipharma Ltd | Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora |
| CN103068824B (zh) | 2010-05-17 | 2017-09-08 | 印蔻真治疗公司 | 作为蛋白激酶调节剂的新型3,5‑二取代‑3h‑咪唑并[4,5‑b]吡啶和3,5‑二取代‑3h‑[1,2,3]三唑并[4,5‑b]吡啶化合物 |
-
2010
- 2010-12-30 RS RS20201567A patent/RS61281B1/sr unknown
- 2010-12-30 MY MYPI2012002974A patent/MY179933A/en unknown
- 2010-12-30 DK DK19151824.0T patent/DK3511330T3/da active
- 2010-12-30 PE PE2020001800A patent/PE20211094A1/es unknown
- 2010-12-30 NZ NZ601128A patent/NZ601128A/en unknown
- 2010-12-30 CN CN201610437304.3A patent/CN106117248B/zh active Active
- 2010-12-30 US US13/501,222 patent/US8987269B2/en active Active
- 2010-12-30 EP EP13198224.1A patent/EP2719699B1/en active Active
- 2010-12-30 ES ES19151824T patent/ES2840454T3/es active Active
- 2010-12-30 EP EP20199091.8A patent/EP3795573B1/en active Active
- 2010-12-30 UA UAA201208929A patent/UA107822C2/ru unknown
- 2010-12-30 EP EP10840591.1A patent/EP2519524A4/en not_active Withdrawn
- 2010-12-30 PL PL19151824T patent/PL3511330T3/pl unknown
- 2010-12-30 BR BR112012016129-6A patent/BR112012016129B1/pt active IP Right Grant
- 2010-12-30 KR KR1020147010967A patent/KR101771299B1/ko active IP Right Grant
- 2010-12-30 DK DK20199091.8T patent/DK3795573T3/da active
- 2010-12-30 KR KR1020127019509A patent/KR101434766B1/ko active IP Right Grant
- 2010-12-30 EP EP19151824.0A patent/EP3511330B1/en active Active
- 2010-12-30 MX MX2012007756A patent/MX336996B/es active IP Right Grant
- 2010-12-30 CU CU20120101A patent/CU24167B1/es active IP Right Grant
- 2010-12-30 PT PT201990918T patent/PT3795573T/pt unknown
- 2010-12-30 HU HUE19151824A patent/HUE052828T2/hu unknown
- 2010-12-30 RS RS20220854A patent/RS63612B1/sr unknown
- 2010-12-30 ES ES20199091T patent/ES2927146T3/es active Active
- 2010-12-30 LT LTEP20199091.8T patent/LT3795573T/lt unknown
- 2010-12-30 HR HRP20221090TT patent/HRP20221090T1/hr unknown
- 2010-12-30 KR KR1020177022937A patent/KR101905350B1/ko active IP Right Grant
- 2010-12-30 CA CA2785749A patent/CA2785749C/en active Active
- 2010-12-30 RS RS20150584A patent/RS54217B1/en unknown
- 2010-12-30 PT PT131982241T patent/PT2719699E/pt unknown
- 2010-12-30 WO PCT/CN2010/080499 patent/WO2011079804A1/en active Application Filing
- 2010-12-30 CN CN201610432059.7A patent/CN106432225B/zh active Active
- 2010-12-30 ES ES13198224.1T patent/ES2546635T3/es active Active
- 2010-12-30 EA EA201691461A patent/EA030141B1/ru not_active IP Right Cessation
- 2010-12-30 SI SI201032046T patent/SI3511330T1/sl unknown
- 2010-12-30 EA EA201200951A patent/EA025466B1/ru not_active IP Right Cessation
- 2010-12-30 ES ES15170608T patent/ES2726152T3/es active Active
- 2010-12-30 EP EP15170608.2A patent/EP2966075B1/en active Active
- 2010-12-30 CN CN201080065014.1A patent/CN102906092B/zh active Active
- 2010-12-30 HU HUE13198224A patent/HUE025504T2/en unknown
- 2010-12-30 PL PL13198224T patent/PL2719699T3/pl unknown
- 2010-12-30 ME MEP-2015-150A patent/ME02211B/me unknown
- 2010-12-30 AU AU2010338712A patent/AU2010338712B2/en active Active
- 2010-12-30 PT PT191518240T patent/PT3511330T/pt unknown
- 2010-12-30 SG SG2012044830A patent/SG181781A1/en unknown
- 2010-12-30 PE PE2016000292A patent/PE20160588A1/es unknown
- 2010-12-30 JP JP2012546344A patent/JP5337313B2/ja active Active
- 2010-12-30 PE PE2012000903A patent/PE20130375A1/es not_active Application Discontinuation
- 2010-12-30 DK DK13198224.1T patent/DK2719699T3/en active
- 2010-12-30 HU HUE20199091A patent/HUE059696T2/hu unknown
- 2010-12-30 SI SI201031021T patent/SI2719699T1/sl unknown
- 2010-12-30 PL PL20199091.8T patent/PL3795573T3/pl unknown
-
2012
- 2012-04-10 US US13/501,224 patent/US8507487B2/en active Active
- 2012-06-14 IL IL220433A patent/IL220433B/en active IP Right Grant
- 2012-06-26 CL CL2012001752A patent/CL2012001752A1/es unknown
- 2012-06-28 GT GT201200220A patent/GT201200220A/es unknown
- 2012-06-29 CO CO12109937A patent/CO6612235A2/es not_active Application Discontinuation
- 2012-06-29 EC EC2012012011A patent/ECSP12012011A/es unknown
- 2012-06-29 NI NI201200118A patent/NI201200118A/es unknown
- 2012-06-29 DO DO2012000188A patent/DOP2012000188A/es unknown
- 2012-07-30 ZA ZA2012/05730A patent/ZA201205730B/en unknown
-
2013
- 2013-06-11 JP JP2013122502A patent/JP2013209418A/ja active Pending
-
2014
- 2014-07-23 HK HK14107500.2A patent/HK1194071A1/xx unknown
-
2015
- 2015-01-21 US US14/601,674 patent/US20150368271A1/en not_active Abandoned
- 2015-06-23 AU AU2015203480A patent/AU2015203480B2/en active Active
- 2015-07-16 IL IL239997A patent/IL239997A/en active IP Right Grant
- 2015-09-08 HR HRP20150952TT patent/HRP20150952T1/hr unknown
- 2015-09-09 SM SM201500213T patent/SMT201500213B/xx unknown
- 2015-09-17 CY CY20151100816T patent/CY1118250T1/el unknown
-
2016
- 2016-04-04 JP JP2016074893A patent/JP6194046B2/ja active Active
- 2016-04-14 HK HK16104273.2A patent/HK1216880A1/zh unknown
- 2016-10-14 US US15/293,722 patent/US9956218B2/en active Active
-
2017
- 2017-08-10 JP JP2017155493A patent/JP6486999B2/ja active Active
-
2018
- 2018-04-04 US US15/945,324 patent/US10512645B2/en active Active
-
2019
- 2019-02-20 JP JP2019028197A patent/JP6647434B2/ja active Active
- 2019-11-08 US US16/678,091 patent/US10946014B2/en active Active
-
2020
- 2020-12-17 HR HRP20202017TT patent/HRP20202017T1/hr unknown
- 2020-12-21 CY CY20201101206T patent/CY1123777T1/el unknown
-
2021
- 2021-02-03 US US17/248,688 patent/US11896592B2/en active Active
-
2023
- 2023-12-13 US US18/538,151 patent/US20240139182A1/en active Pending
